SPOTLIGHT: Wyeth buying ViroPharma shares

Wyeth will buy $10 million in ViroPharma shares after the two collaborators achieved proof-of-concept stage for an experimental hepatitis C therapy. Preliminary data from Phase I should be available by the end of August. Report